Novo Holdings is establishing the REPAIR Impact Fund to replenish the anti-infective pipeline and to combat antimicrobial resistance.

The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund is commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in start-ups, early-stage companies and corporate spin-outs in Europe and the United States involved in discovering and working on early-stage development of therapies targeting antibiotic-resistant microorganisms.

The fund is expected to invest 20-40 million USD per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market.

Who REPAIR will fund

REPAIR will back companies that can change the future of the antibiotic resistance battle: innovative science, driven by a clear product vision and a strong management team and comfortable in a changing regulatory environment. The investment selection and decision process is supported by an international Scientific Selection Board and will give priority to programmes targeting high-priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention.

To apply

The application for proposals will become available on 1 April 2018.